Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.15−0.22 (-1.53%)
Close on Nov 13, 2026Market cap $525.59MP/E –Yield –
Crescent Biopharma cash
Cash and short-term investments held at the end of each period.
Crescent Biopharma's cash was $289.36M at Sep 30, 2026. For fiscal 2025 it was $213.19M, up 513.2% from the year before. Over ten years it grew 16.4% a year on average. The highest annual figure on record is $213.19M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.19M | +513.2% |
| FY2024 | Dec 31, 2024 | $34.77M | -16.8% |
| FY2023 | Dec 31, 2023 | $41.79M | -12.7% |
| FY2022 | Dec 31, 2022 | $47.87M | -47.0% |
| FY2021 | Dec 31, 2021 | $90.25M | -34.1% |
| FY2020 | Dec 31, 2020 | $137.04M | -13.4% |
| FY2019 | Dec 31, 2019 | $158.20M | -24.6% |
| FY2018 | Dec 31, 2018 | $209.92M | +69.4% |
| FY2017 | Dec 31, 2017 | $123.92M | +209.5% |
| FY2016 | Dec 31, 2016 | $40.04M | -14.4% |
| FY2015 | Dec 31, 2015 | $46.80M | -15.2% |
| FY2014 | Dec 31, 2014 | $55.20M | +2288.9% |
| FY2013 | Dec 31, 2013 | $2.31M | -86.7% |
| FY2012 | Dec 31, 2012 | $17.37M | -38.3% |
| FY2011 | Dec 31, 2011 | $28.17M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $289.36M | +117.1% |
| Q2 FY2026 | Jun 30, 2026 | $171.59M | +12.4% |
| Q1 FY2026 | Mar 31, 2026 | $189.16M | +743.4% |
| Q4 FY2025 | Dec 31, 2025 | $213.19M | +513.2% |
| Q3 FY2025 | Sep 30, 2025 | $133.27M | – |
| Q2 FY2025 | Jun 30, 2025 | $152.65M | +581.9% |
| Q1 FY2025 | Mar 31, 2025 | $22.43M | -28.3% |
| Q4 FY2024 | Dec 31, 2024 | $34.77M | -16.8% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $22.39M | -61.4% |
| Q1 FY2024 | Mar 31, 2024 | $31.28M | -51.9% |
| Q4 FY2023 | Dec 31, 2023 | $41.79M | -12.7% |
| Q3 FY2023 | Sep 30, 2023 | $49.41M | -4.3% |
| Q2 FY2023 | Jun 30, 2023 | $58.04M | -3.7% |
| Q1 FY2023 | Mar 31, 2023 | $65.00M | -15.0% |
| Q4 FY2022 | Dec 31, 2022 | $47.87M | -47.0% |
| Q3 FY2022 | Sep 30, 2022 | $51.62M | -49.3% |
| Q2 FY2022 | Jun 30, 2022 | $60.24M | -49.3% |
| Q1 FY2022 | Mar 31, 2022 | $76.52M | -42.2% |
| Q4 FY2021 | Dec 31, 2021 | $90.25M | -34.1% |
| Q3 FY2021 | Sep 30, 2021 | $101.92M | -28.7% |
| Q2 FY2021 | Jun 30, 2021 | $118.85M | -20.7% |
| Q1 FY2021 | Mar 31, 2021 | $132.47M | -14.4% |
| Q4 FY2020 | Dec 31, 2020 | $137.04M | -13.4% |
| Q3 FY2020 | Sep 30, 2020 | $142.87M | -16.4% |
| Q2 FY2020 | Jun 30, 2020 | $149.84M | -18.6% |
| Q1 FY2020 | Mar 31, 2020 | $154.82M | -20.8% |
| Q4 FY2019 | Dec 31, 2019 | $158.20M | -24.6% |
| Q3 FY2019 | Sep 30, 2019 | $170.89M | -22.3% |
| Q2 FY2019 | Jun 30, 2019 | $184.17M | -19.7% |
| Q1 FY2019 | Mar 31, 2019 | $195.56M | -19.4% |
| Q4 FY2018 | Dec 31, 2018 | $209.92M | +69.4% |
| Q3 FY2018 | Sep 30, 2018 | $219.83M | +94.8% |
| Q2 FY2018 | Jun 30, 2018 | $229.43M | +92.6% |
| Q1 FY2018 | Mar 31, 2018 | $242.63M | +601.4% |
| Q4 FY2017 | Dec 31, 2017 | $123.92M | +209.5% |
| Q3 FY2017 | Sep 30, 2017 | $112.87M | – |
| Q2 FY2017 | Jun 30, 2017 | $119.15M | – |
| Q1 FY2017 | Mar 31, 2017 | $34.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $40.04M | – |
See a number that looks wrong?